0001437749-20-024903.txt : 20201204 0001437749-20-024903.hdr.sgml : 20201204 20201204194209 ACCESSION NUMBER: 0001437749-20-024903 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201202 FILED AS OF DATE: 20201204 DATE AS OF CHANGE: 20201204 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kennedy Giulia C CENTRAL INDEX KEY: 0001769333 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36156 FILM NUMBER: 201371086 MAIL ADDRESS: STREET 1: 338 MAIN STREET #26E CITY: SAN FRANCISCO STATE: CA ZIP: 94105 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERACYTE, INC. CENTRAL INDEX KEY: 0001384101 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 205455398 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6000 SHORELINE COURT, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 243-6300 MAIL ADDRESS: STREET 1: 6000 SHORELINE COURT, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: CALDEROME INC DATE OF NAME CHANGE: 20061219 4 1 rdgdoc.xml FORM 4 X0306 4 2020-12-02 0001384101 VERACYTE, INC. VCYT 0001769333 Kennedy Giulia C 6000 SHORELINE COURT SUITE 300 SOUTH SAN FRANCISCO CA 94080 1 Chief Scientific & Med Officer Common Stock 2020-12-02 4 F 0 540 55.08 D 78859 D Common Stock 2020-12-04 4 M 0 5312 9.05 A 84171 D Common Stock 2020-12-04 4 M 0 4406 5.98 A 88577 D Common Stock 2020-12-04 4 M 0 3750 20.21 A 92327 D Common Stock 2020-12-04 4 S 0 3642 55.777 D 88685 D Common Stock 2020-12-04 4 S 0 4279 56.8555 D 84406 D Common Stock 2020-12-04 4 S 0 6094 57.5536 D 78312 D Stock Option (right to buy) 9.05 2020-12-04 4 M 0 5312 0 D 2027-03-02 Common Stock 5312 5313 D Stock Option (right to buy) 5.98 2020-12-04 4 M 0 4406 0 D 2028-03-01 Common Stock 4406 22032 D Stock Option (right to buy) 20.21 2020-12-04 4 M 0 3750 0 D 2029-02-27 Common Stock 3750 33750 D The reporting person is reporting the withholding of 292 and 248 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 587 and 500 Restricted Stock Units, respectively granted on March 2, 2018 and February 28, 2019, respectively, and does not represent a sale by the reporting person. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. Represents weighted average sales price. Sale prices for the transactions range from $55.27 to $56.13. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Represents weighted average sales price. Sale prices for the transactions range from $56.28 to $57.11. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Represents weighted average sales price. Sale prices for the transactions range from $57.31 to $57.90. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. The option becomes exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. The option becomes exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. The option becomes exercisable as to 25% of the shares on February 28, 2020, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. /s/ Keith Kennedy, as Attorney-in-fact 2020-12-04